Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
| Status: | Archived |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2010 |
| End Date: | March 2013 |
A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer
The purpose of this study is to evaluate the therapeutic effectiveness of combination
antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo
equivalent as primary therapy for invasive aspergillosis (IA) in patients with hematological
cancer.
Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous
(IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the
first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be
switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and
gastrointestinal functions are intact.
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
